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ABSTRACT
Precision medicine needs precise phenotypes. The
Human Phenotype Ontology (HPO) uses clinical
signs instead of diagnoses and has become the standard annotation for patients’ phenotypes when describing single gene disorders. Use of the HPO beyond human genetics is however still limited. With
SAMS (Symptom Annotation Made Simple), we want
to bring sign-based phenotyping to routine clinical care, to hospital patients as well as to outpatients. Our web-based application provides access to three widely used annotation systems: HPO,
OMIM, Orphanet. Whilst data can be stored in our
database, phenotypes can also be imported and exported as Global Alliance for Genomics and Health
(GA4GH) Phenopackets without using the database.
The web interface can easily be integrated into local
databases, e.g. clinical information systems. SAMS
offers users to share their data with others, empowering patients to record their own signs and symptoms (or those of their children) and thus provide
their doctors with additional information. We think
that our approach will lead to better characterised
patients which is not only helpful for finding disease
mutations but also to better understand the pathophysiology of diseases and to recruit patients for
studies and clinical trials. SAMS is freely available
at https://www.genecascade.org/SAMS/.

* To

GRAPHICAL ABSTRACT

INTRODUCTION
Many clinical information systems store diagnoses but not
the underlying clinical signs. This leads to a dramatic loss
of information and hampers precision medicine. Patients
suffering from the same disease––or labelled with the same
‘billing diagnosis’––may present very different clinical signs
whilst patients with similar signs may have completely different diagnoses. When it comes to revealing the aetiology
of diseases, a thorough description of the phenotype is indispensable. The same is also essential for a personalised
treatment.
The analysis of phenotypes plays a key role in clinical
practice and medical research, and yet phenotypic descriptions in clinical notes and medical publications are often
imprecise. Deep phenotyping can be defined as the precise
and comprehensive analysis of phenotypic abnormalities in
which the individual components of the phenotype are observed and described (1).
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1. Creation of a Phenopacket on the fly.
2. Use as a database to store and retrieve patients’ phenotypes.
3. Self-phenotyping of patients or their relatives and sharing their data with their doctors.
4. Integration into other applications.

FEATURES
Phenotyping a patient
The obvious main task of SAMS is the sign-based phenotyping of patients. As shown in Figure 1, our interface offers
an autocompletion mode if text is entered to find matches
from the HPO, OMIM and Orphanet. In case of the HPO,
the autocompletion also includes synonyms. Selecting HPO
terms allows users to browse the HPO tree to find closer
matches, e.g. ‘Impaired oral bolus formation’ [HP:0031146]
instead of ‘Dysphagia’ [HP:0002015].
Signs and diseases can be marked as present or absent (i.e.
explicitly excluded by clinical examination).
The interface also offers a simple copy and paste function
to directly insert a list of signs or to copy HPO IDs, e.g. to
include them in a manuscript.
Exporting a Phenopacket
Phenotypic data can either be stored in our database (see below) or exported as a Phenopacket for sharing or use in different applications. If patient data is stored in our database,
all visits will be included in the Phenopacket hence providing a more comprehensive view over the course than data
obtained in a single visit. This is especially important for
non-monogenic disorders where the signs and symptoms
may show many more changes over time than in congenital diseases.
SAMS database
SAMS offers a light-weight database to enter, store, and retrieve patient signs, symptoms, and diagnoses. The database
does not store any other data for each patient, except for
their sex and consanguinity, the date of a visit, and a
pseudonymised ID. The database does not allow storing
names, birth dates or places. In the database mode, users are
able to define as many patients as they wish, add an unlimited number of visits, study the course of diseases and symptoms over time, and export and import phenotypic data in
the new Phenopackets format (12).
To protect patient data, a login is required to use our
database and to share data within the database. All other
functions are available without registration.
Patient course
An unlimited number of patient visits can be stored in the
SAMS database. Whilst the diagnosis is unlikely to change
in most cases, the signs and symptoms a patient presents
may change over time or under treatment. SAMS provides
a graphical view of the patient’s course so that appearance
or disappearance of clinical signs can easily be studied (Figure 2).
Importing data
If the SAMS database is used, patient data can be imported
from Phenopackets. All time points from the Phenopacket
will be included as different visits.
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For a long time, OMIM (2) has been the primary resource
for Mendelian diseases in humans. However, whilst OMIM
descriptions of a disease contain a list of clinical signs, it
remains unclear which signs an individual patient suffering from the disease presents. The same problem arises with
annotations from Orphanet (3) which includes non-genetic
rare diseases as well.
This problem was addressed by the Human Phenotype Ontology (HPO) (4), which offers a hierarchically
structured list of >10 000 clinical signs, along with their
definitions and synonyms. In the last decade, the HPO
has emerged into the standard way of annotating patients suffering from single gene disorders. However, the
HPO is not limited to single gene disorders or rare diseases but also used to characterise complex (‘common’)
diseases (5).
The HPO differs from other available clinical terminologies in several ways. First, the HPO has substantially deeper
and broader coverage of phenotypes than any other clinical
terminology (6), the HPO is not a simple terminology, but
a full OWL (Web Ontology Language) ontology and thus a
computational resource that allows sophisticated analyses,
including logical inference (7). Finally, the HPO-based computational disease models are now indispensable for all current phenotype-driven genomic diagnostics software (e.g.
eXtasy (8), Exomiser (9) or MutationDistiller (10)).
To facilitate the exchange of phenotypic data, the Global
Alliance for Genomics and Health (GA4GH) has recently
suggested the Phenopacket schema. Phenopackets cover
data for diagnosis and research of all types of disease
including Mendelian and complex genetic diseases, cancer and infectious diseases (11). They are designed to be
used across a comprehensive landscape of applications including biobanks, databases and registries, clinical information systems such as Electronic Health Records, genomic
matchmaking, diagnostic laboratories and computational
tools. A Phenopacket is a standard representation of an individual’s medically relevant data, providing a computable
case report of either a single medical encounter or a time
course that can represent the entire medical history of an
individual (12).
In the past, a major challenge to the use of the HPO in
human genetics and other fields has been the lack of userfriendly and simple tools to browse the HPO hierarchy when
phenotyping patients and to store their phenotype (i.e.
present and explicitly absent signs) in a computer-readable
fashion. With SAMS (‘Symptom Annotation Made Simple’), we aim to close this gap, providing both intuitive ontology browsing and search functions as well as a
number of features intended to support translational research. SAMS supports the Phenopacket standard for data
exchange.
SAMS offers four main modes:
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Figure 2. Time-course. This example shows the change of clinical signs in a patient suffering from Systemic lupus erythematosus under therapy. The
diagnosis remains the same but many symptoms disappear.
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Figure 1. Phenotyping interface. Users can enter the signs or diseases they search for and suitable matches will be suggested by autocompletion, including
HPO synonyms. These are the signs and diseases found for ‘swallow’ which lead to the term ‘Dysphagia’. The browse function available for HPO terms
was used to find the more precise sign ‘Impaired oral bolus formation’. On the right, present and absent signs and diseases are shown. The complete record
can either be saved in our database or exported as a Phenopacket.
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Import of Phenopackets is limited to data usable from
SAMS, e.g. signs and symptoms from the HPO and diseases
or diagnoses from OMIM and Orphanet.
SAMS for patients

Sharing data
In addition to exporting phenotypic data as Phenopackets,
users are free to share their records with other SAMS users.
If they choose to share their data from within the database,
they will receive a hyperlink which can be sent to their doctors or collaboration partners. Clicking the hyperlink will
give access to the data. To prevent misuse, these links are
only valid once and for 24 h.
It is not possible to edit shared data but by exporting and
re-importing the patient profile, users can create their own
dataset with full access permissions.
Integration into other applications
The SAMS interface for entering phenotypes can be embedded into other applications, e.g. using an HTML5 iframe
tag (https://www.genecascade.org/sams/iframe.html) without any registration. Phenotypic data can be exported as
a Phenopacket. This allows the integration of SAMS-based
deep phenotyping into local databases without using our
database or transferring patient data beyond signs, symptoms, and diagnoses over the Internet.
Please note that some functions of the SAMS database
(e.g. displaying the time-course of a patient’s record) are not
available using this mode.
DISCUSSION
Thorough phenotyping is a key requisite not only for single gene disorders but also for other diseases: Whilst the
‘billing diagnosis’ will usually not change over time, clinical signs and symptoms may appear or disappear over time
or under therapy. Retrieving them from written reports or
even laboratory measurements is labour-intensive and error
prone. Sign-based phenotypes enable automatic analyses of
the patients, e.g. by finding sub cohorts of patients who had
been labelled with the same ICD-10 diagnosis, or even the
re-diagnosis on the basis of their symptoms. Another advantage is that the use of HPO terms allows a much faster
collection of patients for studies such as clinical trials by
searching for the signs they present or which are absent.

OUTLOOK
We are currently working on the implementation of a
guided differential diagnosis using the patients’ clinical
signs but this is still in an experimental stage and therefore not available yet. For a better discrimination of relevant
signs, we use the frequencies of HPO signs in Orphanet diseases (13).
For patients stored in our database, we will also implement the option to record worsening or improvement for
symptoms that were present in the last visit.
We are also working on implementations of further annotation systems, with MONDO (14) being next.
Another upcoming feature is a granular setting for the
permissions on shared data, i.e. whether or not users may
add visits to shared data or modify the reports.
The software is already designed for using terms in languages other than English and we are working on a German
version but this is still hampered by the state of the German
translation of the HPO. Please contact us if you need other
languages.
DATA AVAILABILITY
SAMS is freely available at https://www.genecascade.org/
SAMS/ and there is no login requirement if the database
is not used.
The database schema and the source code are available for local installation at https://git-ext.charite.de/
genecascade/sams.
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Many patients (or their parents) suffering from rare diseases are keen on providing as much information about
their disease as possible. SAMS allows patients to create
their own account and phenotype themselves (or their children). These data can be shared with their doctors to give
them regular updates about the course of the disease and the
symptoms they encounter. This may lead to a better recording of symptoms or signs that are considered irrelevant by
physicians and are therefore under-documented.
SAMS includes the layperson synonyms for HPO terms
to facilitate the phenotyping process for non-clinicians.

A suitable application of SAMS is to provide concise and
precise information when patients are referred. Using international standards for the description of a patient’s phenotype is less ambiguous than discharge letters may be and
there is less need for translation if different languages are
involved.
Since the database does not store any patient information other than their sex, consanguinity, visit dates, and the
signs/diseases they present, sharing data either directly or
as a Phenopacket does not reveal a patient’s identity as sharing a discharge letter would. Embedding SAMS into remote applications reduces the transferred data to the visit
date and the diseases and clinical signs. We also provide the
source code of SAMS for on-site installation.
So far, SAMS is limited to the Human Phenotype Ontology, OMIM, and Orphanet but we are working on the
integration of further data sources of phenotypic data. This
does explicitly not include treatment data because we want
to keep SAMS focussed and light-weight. With the possibility to use SAMS from within fully-fledged clinical information systems, a connection to further data sources and
in-house medical records can be established.
We hope that a broader use of tools such as SAMS and
the exchange of data using the Phenopacket schema will set
new standards for deep phenotyping and foster research on
and treatment of human diseases.
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4. Robinson,P.N., Köhler,S., Bauer,S., Seelow,D., Horn,D. and
Mundlos,S. (2008) The human phenotype ontology: a tool for
annotating and analyzing human hereditary disease. Am. J. Hum.
Genet., 83, 610–615.
5. Beck,T., Shorter,T. and Brookes,A.J. (2020) GWAS central: a
comprehensive resource for the discovery and comparison of
genotype and phenotype data from genome-wide association studies.
Nucleic Acids Res., 48, D933.
6. Winnenburg,R. and Bodenreider,O. (2014) Coverage of phenotypes
in standard terminologies. In: Joint Bio-Ontologies and BioLINK
ISMB. Citeseer. pp. 41–44.
7. Haendel,M.A., Chute,C.G. and Robinson,P.N. (2018) Classification,
ontology, and precision medicine. N. Engl. J. Med., 379, 1452–1462.

Downloaded from https://academic.oup.com/nar/article/50/W1/W677/6582181 by The Jackson Laboratory Library user on 25 July 2022

REFERENCES

8. Sifrim,A., Popovic,D., Tranchevent,L.-C., Ardeshirdavani,A.,
Sakai,R., Konings,P., Vermeesch,J.R., Aerts,J., De Moor,B. and
Moreau,Y. (2013) eXtasy: variant prioritization by genomic data
fusion. Nat. Methods, 10, 1083–1084.
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